Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents
- 1 November 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Cardiovascular Interventions
- Vol. 11 (11), e006243
- https://doi.org/10.1161/circinterventions.117.006243
Abstract
Background In the large-scale ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents), drug-eluting stent implantation with intravascular ultrasound (IVUS) guidance was associated with a reduction in 1-year rates of stent thrombosis, myocardial infarction (MI), and major adverse cardiac events (cardiac death, MI, or stent thrombosis) compared with angiography guidance alone. We assessed whether the benefits of IVUS guidance were maintained, reduced, or increased at 2 years. Methods and Results ADAPT-DES was a prospective, multicenter, nonrandomized all-comers study of 8582 consecutive patients at 11 US and German sites designed to determine the frequency, timing, and correlates of adverse events after drug-eluting stents. Propensity-adjusted multivariable analysis was performed to examine the impact of IVUS guidance on 2-year outcomes. IVUS guidance (n=3361; 39%) compared with angiography guidance (n=5221; 61%) was associated with reduced 2-year adjudicated rates of (1) major adverse cardiac events (cardiac death, MI, or stent thrombosis; 4.9% versus 7.5%; adjusted hazard ratio, 0.72; 95% CI, 0.59–0.89; P=0.003), (2) definite/probable stent thrombosis (0.55% versus 1.16%; adjusted hazard ratio, 0.40; 95% CI, 0.22–0.73; P=0.003), and (3) MI (3.5% versus 5.6%; adjusted hazard ratio, 0.65; 95% CI, 0.51–0.83; P=0.0006). By landmark analysis, IVUS guidance compared with angiography guidance was also associated with significantly reduced rates of major adverse cardiac events, MI, stent thrombosis, and clinically driven target lesion revascularization between 1 and 2 years after drug-eluting stent implantation. The number needed to treat with IVUS guidance to prevent 1 major adverse cardiac event was reduced from 64 (42–137) at 1 year to 41 (29–69) at 2 years. Conclusions In ADAPT-DES, the early improvement in event-free survival after drug-eluting stent implantation with IVUS guidance compared with angiography guidance was further increased with longer term follow-up to 2 years. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT00638794.Keywords
This publication has 21 references indexed in Scilit:
- Effect of Intravascular Ultrasound–Guided vs Angiography-Guided Everolimus-Eluting Stent ImplantationJAMA, 2015
- Meta-Analysis of Outcomes After Intravascular Ultrasound–Guided Versus Angiography-Guided Drug-Eluting Stent Implantation in 26,503 Patients Enrolled in Three Randomized Trials and 14 Observational StudiesThe American Journal of Cardiology, 2014
- Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve OutcomeJACC: Cardiovascular Interventions, 2014
- Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting StentsCirculation, 2014
- Use of IVUS guided coronary stenting with drug eluting stentInternational Journal of Cardiology, 2013
- Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry studyThe Lancet, 2013
- Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patientsEuroIntervention, 2012
- The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationaleAmerican Heart Journal, 2008
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationaleAmerican Heart Journal, 2004